Katana Labs is a German DeepTech and AI startup, founded in 2023. We combine extensive expertise in software engineering, machine learning, agentic AI, clinical research, oncology, digital pathology, and business. United by one mission, making chronic and complex diseases curable, we believe in the power of multi-omics data to advance precision medicine. By leveraging cutting-edge software and pioneering AI technologies we empower subject matter experts, like researchers and clinical scientists, in their quest to decode biology and derive a much better understanding of the multidimensional data deeply embedded in tissue samples.
Katana Labs develops best-in-class deep learning model for the automated analysis of large image datasets. These models are designed to meet the specific needs of various applications in advanced histopathology and tissue analysis, including accurate cell segmentation, biomarker quantification, and multidimensional data extraction. Made readily available through Katana Labs’ cloud platform Katana Edge, R&D teams can easily explore, analyze, and collaborate on whole slide images and tissue microarrays directly via a browser-based interface. By automating time-consuming processing, segmentation, and bioinformatics tasks, Katana Labs’ AI platform AI platform Katana Edge enables R&D teams to enhance workflow efficiency and productivity in life sciences, translational and clinical research as well as in the biopharma industry.
Backed by experienced investors, business angels, and advisors, we are committed to provide AI-enhanced solutions that help to make sense out of complex biological datasets and improve our understanding of how to counteract complex diseases.
Katana Labs is co-financed by the European Union, from tax revenues on the basis of the budget adopted by the Saxon State Parliament, by Sächsische Aufbaubank (SAB) and by Technologiegründerfonds Sachsen (TGFS) via the TGFS Basic fund. Katana Labs is also member of Biosaxony via leap:up accelerator:
